AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00214019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo diskus
Trial: NCT04515290
Drug: TSG-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of TSG-01 (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; High dose group.
Trial: NCT04515290
Drug: TSG-01 and Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of TSG-01 (0.35g/tablet) and one tablet of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; Low dose group.
Trial: NCT04515290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks.
Trial: NCT00669877
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) starting after rituximab completed (odd courses).
Trial: NCT00669877
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
Trial: NCT01706211
Drug: BRL 49653C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRL 49653C 2 mg bid or placebo bid through weeks 1 to 24.
Trial: NCT01706211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01352234
Drug: Acetylsalicylic Acid 160 mg
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule containing Acetylsalicylic Acid 160mg pill with lactose
Trial: NCT01352234
Drug: Acetylsalicylic Acid 80 mg
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule containing Acetylsalicylic Acid 80mg pill with lactose
Trial: NCT00669877
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 after the completion of Rituximab.
Trial: NCT01492153
Drug: isophane human insulin
RxNorm normalized name: insulin isophane, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
Trial: NCT01492153
Drug: human soluble insulin
RxNorm normalized name: Recombinant human soluble insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
Trial: NCT00311155
Drug: olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.
Trial: NCT03017235
Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied as two 160 mL ready-to-drink bottles, per subject, without further reconstitution, before administration.
Trial: NCT02534571
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: epinephrine injection endoscopically \<20 mls
Trial: NCT01646177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03536507
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Trial: NCT01005069
Drug: DLBS-32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DLBS-32 50 mg once daily and lifestyle modification
Trial: NCT01005069
Drug: DLBS-32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DLBS-32 100 mg once daily and lifestyle modification
Trial: NCT01005069
Drug: DLBS-32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DLBS-32 200 mg once daily and lifestyle modification
Trial: NCT01005069
Drug: DLBS-32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DLBS-32 300 mg once daily and lifestyle modification
Trial: NCT01005069
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules once daily and lifestyle modification
Trial: NCT00519246
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol tartrate 1 mg i.v.
Trial: NCT00519246
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol Tartrate 2 mg i.v.
Trial: NCT02351440
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00004928
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00440180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT00259818
Drug: EM-1421
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01529320
Drug: Adventan® (methylprednisolone aceponate 0,1%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses: 1/4 FTU (Finger Tip Unit) during 5 days (Day 7-Day 11). Procedure: Patch Test (Nickel sulphate 5%) during 2 days (Day 0- Day 2.
Trial: NCT02200653
Drug: High dose of MICARDIS®, once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02200653
Drug: Low dose of MICARDIS®, once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02200653
Drug: Low dose of COZAAR® / LORZAAR®, once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02200653
Drug: High dose of COZAAR® / LORZAAR®, once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02200653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00368927
Drug: sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT04521751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo capsules
Trial: NCT00360295
Drug: Azithromycin SR
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04398823
Drug: Sclersing liqiud of Lauromacrogol
RxNorm normalized name: lauromacrogols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in LS will receive enteroscopy with the sclerosing liquid of lauromacrogol.
Trial: NCT00009659
Drug: CDB 2914
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02229851
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.
Trial: NCT03235752
Drug: TJ301 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ301 300mg IV infusion
Trial: NCT03235752
Drug: TJ301 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ301 600mg IV infusion
Trial: NCT03235752
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV infusion
Trial: NCT00074477
Drug: R092670
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00613743
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo solution Quinine diHCl 0.3% at 50 mg/15 ml mouthwash 6 time/day
Trial: NCT03211117
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00249964
Drug: Combination Treatment - Cohort 1
RxNorm normalized name: Combinations of drugs for treatment of tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 75 mg/m2 per day from day 2 to day 6.
Trial: NCT00249964
Drug: Combination Treatment - Cohort 2
RxNorm normalized name: Combinations of drugs for treatment of tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 100 mg/m2 per day from day 2 to day 6.
Trial: NCT00249964
Drug: Combination Treatment - Cohort 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 125 mg/m2 per day from day 2 to day 6.
Trial: NCT00249964
Drug: Combination Treatment - Cohort 4
RxNorm normalized name: Combinations of drugs for treatment of tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 150 mg/m2 per day from day 2 to day 6.
Trial: NCT03617900
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose monohydrate 400 mg/capsules
Trial: NCT00831662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One to two drops in each eye QID for 6 weeks
Trial: NCT01854294
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
Trial: NCT03360448
Drug: Ad5.hAC6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
Trial: NCT03360448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
Trial: NCT01675453
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02169895
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02169895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02169895
Drug: Prolopa®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa/benserazide 100/25 mg
Trial: NCT02342314
Drug: Placebo (Part A and Part B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via SC injection
Trial: NCT03312413
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.5 mL·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
Trial: NCT01260818
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100ml saline is kept in wound for 2 hours before drainage is opened postoperatively
Trial: NCT00443170
Drug: omeprazole, caffeine, flurbiprofen, rosiglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02628028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00447564
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 implants
Trial: NCT02145468
Drug: Placebo twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo as film-coated, round, plain faced tablets.
Trial: NCT02145468
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
Trial: NCT00673621
Drug: Technosphere Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin
Trial: NCT00673621
Drug: Methacholine chloride
RxNorm normalized name: Methacholine Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%
Trial: NCT01640639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, pill, once p.d., 6 weeks
Trial: NCT02498912
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00316017
Drug: 7.5% hypertonic saline (HS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 cc dose given as a one-time IV bolus in the pre-hospital setting.
Trial: NCT00316017
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 cc dose given as a one-time IV bolus in the pre-hospital setting.
Trial: NCT04176133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) single dose administration, no active ingredient. A matching placebo is provided as a sterile, clear, colorless to slightly yellow liquid for IM injection in prefilled vials that are identical in appearance to the vials containing active drug.
Trial: NCT04176133
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
Trial: NCT01468181
Drug: LY2189265
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01468181
Drug: Sulfonylureas (SU)
RxNorm normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU is a pre-study prescribed dose and is not being provided as part of the trial.
Trial: NCT01468181
Drug: alpha-glucosidase inhibitor (a-GI)
RxNorm normalized name: alpha glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a-GI is a pre-study prescribed dose and is not being provided as part of the trial.
Trial: NCT01468181
Drug: Glinides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glinides is a pre-study prescribed dose and is not being provided as part of the trial.
Trial: NCT02419547
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
Trial: NCT01645332
Drug: Placebo of DLBS3233
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of DLBS3233 once daily for 12 weeks
Trial: NCT01645332
Drug: DLBS3233
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg DLBS3233 once daily for 12 weeks
Trial: NCT00239018
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00349362
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustanon- 200mg intramuscular testosterone
Trial: NCT00349362
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline intramuscular injection every two weeks
Trial: NCT00763997
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day
Trial: NCT00005945
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00763997
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day
Trial: NCT02957032
Drug: F16IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients first receive an initial run-in dose of 30 Mio IU of F16IL2 on day 1 and escalating doses of F16IL2 on day 1, 8, 15 and 22.~Treatment will be repeated every 28 days for up to three cycles.
Trial: NCT00005945
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose 25 g/m² IV Days 0, 7, 14, given over a period of 15 minutes to 2 hours
Trial: NCT00763997
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day
Trial: NCT02108964
Drug: EGF816
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF816 will be dosed once daily. On the first day of each treatment cycle, the patient receives an adequate drug supply for self-administration at home. The investigator will instruct the patient to take EGF816 exactly as prescribed.
Trial: NCT00005945
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00763997
Drug: Parecoxib/Valdecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day
Trial: NCT00005945
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO and IT
Trial: NCT00896597
Drug: NRL972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg NRL972 in 5 mL solution for injection administered as a 15-second intravenous injection on each of four occasions.
Trial: NCT00777764
Drug: Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In a saline solution, full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:100,000 and 1:10,000 were followed by 20 minutes of observation.~For the skin prick test, participants were tested initially by positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were made in saline.
Trial: NCT00581893
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin will be dosed to a target dose of 5 mg/kg qhs for one month
Trial: NCT00581893
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03663673
Drug: EpiCeram
RxNorm normalized name: EPICERAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
Trial: NCT03663673
Drug: Aveeno Daily Moisturising Sheer Hydration Lotion®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
Trial: NCT00003397
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02706405
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04496245
Drug: Broncho-Vaxom®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broncho-Vaxom adult capsules® (OM85)
Trial: NCT04394377
Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine full anticoagulation strategy
Trial: NCT05190783
Drug: TheraCal
RxNorm normalized name: TheraCal D2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: light cured resin modified calcium silicate filled liner designed for use in direct and indirect pulp capping
Trial: NCT02304705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule three times daily by mouth for 90 days
Trial: NCT01896427
Drug: 21-benzyloxy-9alpha-fluoro-16alpha-methylpregna-1,4-dien-11beta,17alpha-diol-3,20-dione
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of dexamethasone (8mg) will injected
Trial: NCT04020185
Drug: IMSA101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.